Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 25
Filter
1.
J Gastrointest Cancer ; 54(1): 62-66, 2023 Mar.
Article in English | MEDLINE | ID: mdl-35000070

ABSTRACT

PURPOSE: Colorectal cancer (CRC) is the third most common cancer in the world, with enhancing morbidity and mortality each year. Due to the drug resistance against CRC, the use of novel compounds besides chemotherapy is required. Natural seafood contains large amounts of biologically active substances with new chemical structures and new medicinal activities. The aim of this study was to evaluate the effects of hydroalcoholic extract of Sargassum oligocystom algae on SW742, HT-29, WiDr, and CT-26 CRC cell lines, and to evaluate the expression of P53 and APC genes using quantitative real-time PCR (RT-qPCR). METHODS: The cytotoxicity of S. oligocystom hydroalcoholic extract was determined by MTT and trypan blue methods in six different concentrations including 0.1, 0.2, 0.5, 1, 2, and 4 mg/mL on various CRC cell lines and a control group. The expression of P53 and APC genes in exposure to 2 mg/mL of the extract was also evaluated using RT-qPCR. RESULTS: The LD50 and LD90 of S. oligocystom included 0.5-1 and > 2 mg/mL, respectively mostly affecting SW742 and CT-26 cells. In the trypan blue test, 90% viability and death of cells were observed at 0.1 and 4 mg/mL of extract, respectively. The 2 mg/mL was a safe cytotoxic concentration. A significant viability decrease was observed at concentrations ≥ 1 mg/mL (p < 0.001). Sargassum oligocystom extract at 2 mg/mL significantly increased the expression of APC ranging 1.98-2.2-fold (p < 0.001) but not P53 gene which ranged 0.5-0.68-fold (p = 0.323) after 24 h. CONCLUSION: These results indicated that the brown algae S. oligocystom extract had significant antitumor effects against the SW742, HT-29, WiDr, and CT-26 CRC cell lines and especially CT-26, suggesting that it may be a potential candidate for further studies and therefore designing drugs of natural anticancer origin. The S. oligocystom had an anticancer effect via an increase in the APC gene expression.


Subject(s)
Colorectal Neoplasms , Sargassum , Humans , Apoptosis , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Genes, APC , HT29 Cells , Sargassum/chemistry , Tomography, X-Ray Computed , Trypan Blue/pharmacology , Trypan Blue/therapeutic use
2.
Mol Med Rep ; 26(1)2022 Jul.
Article in English | MEDLINE | ID: mdl-35621135

ABSTRACT

The prognosis of glioblastoma, which is the most frequent type of adult­onset malignant brain tumor, is extremely poor. Therefore, novel therapeutic strategies are needed. Previous studies report that JCI­20679, which is synthesized based on the structure of naturally occurring acetogenin, inhibits mitochondrial complex I and suppresses the growth of various types of cancer cells. However, the efficacy of JCI­20679 on glioblastoma stem cells (GSCs) is unknown. The present study demonstrated that JCI­20679 inhibited the growth of GSCs derived from a transposon system­mediated murine glioblastoma model more efficiently compared with the growth of differentiation­induced adherent cells, as determined by a trypan blue staining dye exclusion test. The inhibition of proliferation was accompanied by the blockade of cell­cycle entry into the S­phase, as assessed by a BrdU incorporation assay. JCI­20679 decreased the mitochondrial membrane potential, suppressed the oxygen consumption rate and increased mitochondrial reactive oxygen species generation, indicating that JCI­20679 inhibited mitochondrial activity. The mitochondrial inhibition was revealed to increase phosphorylated (phospho)­AMPKα levels and decrease nuclear factor of activated T­cells 2 (NFATc2) expression, and was accompanied by a decrease in calcineurin phosphatase activity. Depletion of phospho­AMPKα by knockdown of AMPKß recovered the JCI­20679­mediated decrease in NFATc2 expression levels, as determined by western blotting and reverse transcription­quantitative PCR analysis. Overexpression of NFATc2 recovered the JCI­20679­mediated suppression of proliferation, as determined by a trypan blue staining dye exclusion test. These results suggest that JCI­20679 inhibited mitochondrial oxidative phosphorylation, which activated AMPK and reduced NFATc2 expression levels. Moreover, systemic administration of JCI­20679 extended the event­free survival rate in a mouse model transplanted with GSCs. Overall, these results suggested that JCI­20679 is a potential novel therapeutic agent against glioblastoma.


Subject(s)
Glioblastoma , AMP-Activated Protein Kinases/metabolism , Animals , Cell Proliferation , Glioblastoma/drug therapy , Glioblastoma/genetics , Glioblastoma/metabolism , Mice , Neoplastic Stem Cells/metabolism , Trypan Blue/metabolism , Trypan Blue/therapeutic use
3.
Acta Ophthalmol ; 100(2): e598-e608, 2022 Mar.
Article in English | MEDLINE | ID: mdl-33998147

ABSTRACT

PURPOSE: To report the long-term outcomes of large diameter epiretinal lyophilized amniotic membranes (lAMs) in recurrent or persistent macular holes (MHs) with or without rhegmatogenous retinal detachment (RRD), in a prospective interventional case series. METHODS: Ten eyes of 10 patients underwent pars plana vitrectomy for MH-associated RRD (n = 5) or persistent MH without RRD (n = 5), in a university Hospital. A 3 or 4 mm diameter disc of lAM, stained with 0.06% trypan blue, was inserted with a catheter through a sclerotomy and positioned over the MH. Gas or silicone-oil tamponade was used. At 1 year, the main outcome was anatomic success defined as complete MH closure. Secondary outcomes were best corrected visual acuity (BCVA) recovery, changes in ellipsoid zone (EZ) and external limiting membrane (ELM) defects, complications. Mean follow-up was 13.8 ± 2.9 months (range, 12-18). RESULTS: Mean baseline data were minimum and maximum diameters, respectively, 945 ± 330 and 1507 ± 717 µm; axial length 26.58 ± 3.38 mm; and number of prior surgeries 1.4 ± 0.96. At 1 year, anatomic success was achieved in eight eyes (80%), and two had reduced diameter of MH. All RRDs were reattached without recurrence. Mean logMAR BCVA improved from 1.92 ± 0.58 to 1.17 ± 0.57 (p < 0.001), with nine eyes (90%) achieving ≥0.3 logMAR improvement. Mean EZ and ELM defects decreased (p = 0.004, p = 0.003, respectively). Postoperative complications were RRD (n = 1) reattached by subsequent surgery, lAM slightly retracted under silicone (n = 1), foveal atrophy after early lAM displacement (n = 1). CONCLUSION: A 1-year follow-up highlighted that epiretinal large discs of blue-stained lAM can help safely close refractory MHs, and provide satisfactory visual recovery.


Subject(s)
Retinal Perforations/surgery , Trypan Blue/therapeutic use , Vitrectomy/methods , Aged , Amnion/transplantation , Female , Humans , Male , Middle Aged , Prospective Studies , Retinal Perforations/diagnostic imaging , Retinal Perforations/pathology
4.
Int Immunopharmacol ; 81: 106263, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32028243

ABSTRACT

Pathological ß-amyloid (Aß)-induced microglial activation could cause chronic neuroinflammation in the brain of Alzheimer's disease (AD) patients, and has been considered as one of the main pathological events of this disease. Chicago sky blue 6B (CSB6B), a pigment used in biochemical staining, has been reported to produce analgesic effects in neuroinflammatory-associated pain models. We have previously found that CSB6B could directly inhibit Aß aggregation and prevent Aß toxicity in neurons. However, it remains unclear whether this compound could prevent Aß-induced neuroinflammation and impairments of learning and memory in the AD models. In this study, CSB6B was found to effectively inhibit the production of pro-inflammatory cytokines, including tumor necrosis factor-α and interleukin-1ß, without affecting cell viability in BV2 microglia cells stimulated by Aß oligomer and lipopolysaccharide. Moreover, CSB6B significantly reduced mRNA expression of inducible nitric oxide synthase and increased mRNA expression of arginase-1, suggesting that CSB6B might promote the polarization of BV2 cells into M2 phenotype. In Aß oligomer-treated mice, hippocampal injection of CSB6B prevented cognitive impairments, and attenuated pro-inflammatory cytokines production. In addition, CSB6B inhibited nuclear transcription factor-κB (NF-κB), and restrainedthe activation of NOD-like receptor pyrin domain containing-3 (NLRP3) both in vitro and in vivo. According to our results, CSB6B may counteract Aß-induced cognitive impairments and neuroinflammation by inhibiting NF-κB and NLRP3. Combined with previous studies, we anticipated that CSB6B may further develop into a potential anti-AD drug with multiple functions on neurons and microglia cells, concurrently.


Subject(s)
Alzheimer Disease/drug therapy , Anti-Inflammatory Agents/therapeutic use , Cognitive Dysfunction/drug therapy , Microglia/metabolism , Neurogenic Inflammation/drug therapy , Neurons/metabolism , Trypan Blue/therapeutic use , Amyloid beta-Peptides/immunology , Animals , Cell Line , Cytokines/metabolism , Humans , Inflammation Mediators/metabolism , Mice , Mice, Inbred ICR , Microglia/pathology , NF-kappa B/metabolism , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Neurons/pathology , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism
5.
J Bras Nefrol ; 41(3): 315-322, 2019.
Article in English, Portuguese | MEDLINE | ID: mdl-30720852

ABSTRACT

INTRODUCTION: It is hypothesized that increased macrophage migration inhibitory factor (MIF) expression may contribute to diabetic nephropathy (DN) pathogenesis. The aim of the present study was to investigate the renal effects of MIF inhibition in a diabetic experimental model. METHODS: Eighteen male Wistar rats (230 ± 20 g) were divided into three groups: 1) control, 2) diabetic (STZ, 50 mg/kg, dissolved in saline, ip), 3) diabetic + MIF antagonist (p425, 1 mg/kg per day, ip, on the 21th day, for 21 consecutive days). The treatment started since we founwd a significant increase in urine albumin excretion (UAE) rate in the diabetic rats in comparison with the control rats. The rats were kept individually in metabolic cages (8 AM-2 PM) and urine samples were collected in the 21 and 42th day. At the end, blood and tissue samples were collected for biochemical (BS, UPE, urine GAG, BUN, Cr, Na, and K) and histological analyses. RESULTS: The results of this study showed that MIF antagonist (p425) significantly decreased urine protein and GAG excretion, urine protein/creatinine ratio, and serum BUN and Cr in the streptozotocin-induced DN in the rats. Pathological changes were significantly alleviated in the MIF antagonist (p425)-administered DN rats. CONCLUSION: Collectively, these data suggested that MIF antagonist (p425) was able to protect against functional and histopathological injury in the DN.


Subject(s)
Diabetes Mellitus, Experimental/pathology , Diabetic Nephropathies/drug therapy , Intramolecular Oxidoreductases/antagonists & inhibitors , Macrophage Migration-Inhibitory Factors/antagonists & inhibitors , Protective Agents/pharmacology , Protective Agents/therapeutic use , Trypan Blue/pharmacology , Trypan Blue/therapeutic use , Albuminuria/drug therapy , Animals , Blood Glucose , Creatinine/blood , Creatinine/urine , Diabetes Mellitus, Experimental/blood , Diabetes Mellitus, Experimental/chemically induced , Diabetes Mellitus, Experimental/urine , Diabetic Nephropathies/blood , Diabetic Nephropathies/pathology , Diabetic Nephropathies/urine , Disease Models, Animal , Glycosaminoglycans/urine , Kidney/pathology , Macrophage Activation , Male , Rats , Rats, Wistar , Streptozocin/pharmacology
6.
Clin Hemorheol Microcirc ; 69(1-2): 327-336, 2018.
Article in English | MEDLINE | ID: mdl-29630545

ABSTRACT

BACKGROUND: Drug-induced liver injury (DILI) is the most common reason for withdrawal of anticancer drugs from the market. To prevent adverse side effects of drugs, it is important to investigate potential toxicity in vitro. However, outcome of cytotoxicity screenings can differ remarkably depending on the method used. OBJECTIVE: We aimed to compare XTT, ATP-based CellTiter-Glo®2.0 and trypan blue exclusion (TBE) assays regarding their sensitivity in detecting acute cytotoxicity on HepG2 cells after incubation with the classical anticancer drugs Taxol and Imatinib or with the proteasome inhibitor MG-132. METHODS: HepG2 cells were treated for 48 h and cell viability was analysed by XTT, CellTiter-Glo®2.0 or TBE assay. RESULTS: All tested compounds showed a reduction of viability of HepG2 cells. However, assay results differed significantly: Both ATP-based and TBE assay showed concentration-dependent cytotoxic effects, but outcomes were less pronounced with TBE. In contrast, the widely used XTT assay did not detect any acute cytotoxicity of Taxol and Imatinib. CONCLUSIONS: Acute cytotoxic effects of tested compounds could be revealed. However, results were significantly different from each other with ATP assay being the most sensitive one under the conditions tested. Thus, acute cytotoxicity can be dramatically underestimated if only standard XTT test is used.


Subject(s)
Antineoplastic Agents, Phytogenic/pharmacology , Carcinoma, Hepatocellular/drug therapy , Imatinib Mesylate/pharmacology , Liver Neoplasms/drug therapy , Paclitaxel/pharmacology , Proteasome Inhibitors/pharmacology , Trypan Blue/therapeutic use , Antineoplastic Agents/pharmacology , Biological Assay , Carcinoma, Hepatocellular/pathology , Cell Line, Tumor , Cell Survival/drug effects , Humans , Liver Neoplasms/pathology
7.
J Cataract Refract Surg ; 42(12): 1774-1778, 2016 12.
Article in English | MEDLINE | ID: mdl-28007109

ABSTRACT

PURPOSE: To study the effect of trypan blue on lens capsule elasticity and ease of completing a continuous curvilinear capsulorhexis (CCC) in a sheep lens model and to subsequently observe the effects of trypan blue in the surgical setting of 3 pediatric patients. SETTING: State University of New York, Downstate Medical Center, Brooklyn, New York, USA. DESIGN: Prospective case series. METHODS: Twenty-four lenses were excised from fresh sheep globes. Twelve lenses were immersed in trypan blue for 2.5 minutes, and 12 lenses were immersed in a balanced salt solution for 2.5 minutes. Ease of completion of CCC was graded, and intralenticular pressure was quantified. A pediatric cataract surgeon used trypan blue to stain the lens capsules of 3 children during cataract surgery. The surgeon noted the effects of trypan blue on capsule elasticity and on the ease of completion of the CCC. RESULTS: Lenses immersed in trypan blue had a mean score of 2.58 in ease of completion of capsulorhexis compared with the control group (1.5) (P = .031). Capsulorhexis was successfully completed in 91.7% of trypan blue cases compared with 58.3% of controls. Immersion in trypan blue decreased the intralenticular pressure by a mean of 4.5 mm Hg (P = .025). Successful capsulorhexis was completed in the 3 pediatric cases. CONCLUSION: Trypan blue improved the success rate of CCC completion in the sheep lens by decreasing lens capsule elasticity. FINANCIAL DISCLOSURE: None of the authors has a financial or proprietary interest in any material or method mentioned.


Subject(s)
Capsulorhexis/methods , Coloring Agents/therapeutic use , Trypan Blue/therapeutic use , Animals , Cataract , Child , Humans , Models, Animal , Prospective Studies , Staining and Labeling
8.
Biotech Histochem ; 89(8): 564-7, 2014 Nov.
Article in English | MEDLINE | ID: mdl-24867494

ABSTRACT

Trypan blue is colorant from the 19(th) century that has an association with Africa as a chemotherapeutic agent against protozoan (Trypanosomal) infections, which cause sleeping sickness. The dye still is used for staining biopsies, living cells and organisms, and it also has been used as a colorant for textiles.


Subject(s)
Staining and Labeling/methods , Textiles , Trypan Blue/chemistry , Trypan Blue/therapeutic use , Trypanosomiasis, African/drug therapy , Animals , Antiprotozoal Agents/adverse effects , Antiprotozoal Agents/therapeutic use , Coloring Agents/adverse effects , Coloring Agents/therapeutic use , Humans , Trypan Blue/adverse effects
9.
Biotech Histochem ; 85(6): 341-54, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21080764

ABSTRACT

Trypanosomiasis, a group of diseases including sleeping sickness in humans and Nagana in cattle in Africa, and Chagas' disease in South America, remains a considerable problem in the 21(st) century. The therapies that are available, however, usually have their roots in the "dye therapy" of a century ago, knowledge gained at the microscope from parasite staining procedures and converted to chemotherapy based on compounds closely related to the laboratory reagents. Dyes such as trypan red and trypan blue led to the development of suramin, while cationic nitrogen heterocyclic dyes furnished examples of the phenanthridinium class, such as ethidium (homidium) and isometamidium. Both suramin and isometamidium remain in use. Owing to mutagenicity issues, the presence of ethidium among the phenanthridinium dyes has led to concerns over the clinical use of related derivatives. There are several mechanisms for dye-DNA interaction, however, including possible hydrogen bonding of dye to the polymer, and these are discussed together with structure-activity relations and cellular localization of the phenanthridine and isomeric acridines involved. Better understanding of nucleic acid binding properties has allowed the preparation of more effective phenanthridinium analogues intended for use as anticancer/antiviral therapy.


Subject(s)
Chagas Disease/drug therapy , DNA/chemistry , Phenanthridines/chemistry , Phenanthridines/therapeutic use , Trypanocidal Agents/history , Trypanosomiasis, African/drug therapy , Acridines/chemistry , Acridines/history , Acridines/therapeutic use , Africa , Animals , Azo Compounds/therapeutic use , Cattle , History, 19th Century , History, 20th Century , Humans , Hydrogen Bonding , Intercalating Agents/chemistry , Intercalating Agents/history , Intercalating Agents/therapeutic use , Phenanthridines/history , South America , Suramin/chemistry , Suramin/therapeutic use , Trypan Blue/therapeutic use , Trypanocidal Agents/therapeutic use , Trypanosoma congolense/drug effects , Trypanosoma cruzi/drug effects
10.
Retina ; 29(8): 1111-8, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19491726

ABSTRACT

PURPOSE: To assess whether reading ability and microperimetry improve as demonstrated for visual acuity after surgery for macular hole and macular pucker. METHODS: Fifty-nine consecutive patients underwent pars plana vitrectomy for macular pucker (n = 41) or full-thickness macular holes (n = 18). Functional assessment was made at 3, 6, and 12 months after surgery and included far visual acuity (Early Treatment Diabetic Retinopathy Study charts), retinal sensitivity using the microperimeter (MP1, Nidek Technologies, Padova, Italy), and reading ability (MNRead charts). RESULTS: An improvement was recorded both for macular holes and puckers not only for visual acuity, but also for reading acuity and mean central retinal sensitivity (P < 0.01 for the overall comparisons between baseline and follow-up values). Maximum reading speed was already good at baseline both for puckers and holes overall, and a significant mean improvement was recorded only in patients with macular hole at 6 and 12 months (P < 0.01). Although eyes with macular holes had worse baseline visual function compared with puckers (P < 0.01 for all measures of visual function except for reading speed), they recovered to similar levels thanks to greater improvement (P < 0.05 for the difference in improvement during follow-up between puckers and holes for all measures of visual function). No differences were found among indocyanine green or trypan blue staining compared with no staining for internal limiting membrane removal based on all outcome measures (P > 0.05 for the overall difference of visual function improvement during follow-up). CONCLUSION: The improvement found for visual acuity after vitrectomy for macular hole and pucker also regards retinal sensitivity and reading ability for up to 12 months. This is reassuring concerning the benefits for the patients, and this shows that visual acuity is a valid functional measure for investigating the efficacy of macular surgery.


Subject(s)
Reading , Retina/physiology , Retinal Perforations/surgery , Aged , Coloring Agents/therapeutic use , Humans , Indocyanine Green/therapeutic use , Quality of Life , Retina/surgery , Retinal Perforations/psychology , Treatment Outcome , Trypan Blue/therapeutic use , Visual Acuity , Vitrectomy/methods
11.
J Fr Ophtalmol ; 30(9): 914-7, 2007 Nov.
Article in French | MEDLINE | ID: mdl-18046275

ABSTRACT

OBJECTIVE: To study the results of phacoemulsification in eyes with white cataract using trypan blue for capsule staining. PATIENTS AND METHODS: Thirty patients who had white cataract were included in this prospective study. They had phacoemulsification and continuous curvilinear capsulorhexis using trypan blue. Intraoperative problems related to capsulorhexis and phacoemulsification as well as postoperative outcomes where analyzed. Postoperative examinations were done at 1 day, 1 week, and 1, 3, 6, and 12 months. The mean follow-up was 10 months. RESULTS: Complet capsulorhexis was achieved in 26 cases. Intraoperative complications included incomplet capsulorhexis in four cases (13.3%) and conversion to a conventional extraction technique in two cases. There were no cases of posterior capsular tear. Twenty-eight eyes (93.3%) had a final best corrected visual acuity at 8/10 or better. Postoperative complications included moderate transient corneal edema in six cases (20%) and iritis in three cases (10%). There were no complications related to the use of trypan blue. CONCLUSION: Phacoemulsification using trypan blue was safe and effective in managing white cataract and had a high success rate.


Subject(s)
Capsulorhexis/methods , Coloring Agents/therapeutic use , Phacoemulsification/methods , Trypan Blue/therapeutic use , Adult , Aged , Aged, 80 and over , Cataract/classification , Cataract/pathology , Female , Humans , Male , Middle Aged , Phacoemulsification/adverse effects , Prospective Studies , Treatment Outcome , Visual Acuity
13.
J Cataract Refract Surg ; 31(10): 1867-9, 2005 Oct.
Article in English | MEDLINE | ID: mdl-16338552

ABSTRACT

Use of trypan blue for penetrating keratoplasty was developed to facilitate the procedure. Trypan blue is injected before and after the addition of 0.25 mL of an ophthalmic viscosurgical device (OVD), sodium hyaluronate, to stain the internal and external cut edge of the cornea as well as the OVD, enabling the surgeon to improve visualization of the incision and suture depth, improve alignment of host and donor tissues, and ensure that all OVD is removed.


Subject(s)
Coloring Agents/therapeutic use , Keratoplasty, Penetrating/methods , Trypan Blue/therapeutic use , Coloring Agents/administration & dosage , Humans , Hyaluronic Acid/therapeutic use , Injections , Staining and Labeling , Suture Techniques , Trypan Blue/administration & dosage
14.
Arq. bras. oftalmol ; 64(4): 333-335, jul.-ago. 2001. tab
Article in English | LILACS | ID: lil-292584

ABSTRACT

Purpose: To describe the use of anterior capsule staining in cataracts without red reflex using a 0.025 percent trypan blue solution. Methods: Six eyes of 6 patients with cataracts without red reflex were submitted to phacoemulsification using a direct injection of 0.2 to 0.5 ml of 0.025 percent trypan blue in the anterior chamber previous to viscoelastic injection. All patients had an ophthalmologic examination prior to surgery, as well as pre and postoperative corneal endothelial cell count. Results:In all cases the capsule became stained with a faint blue color that enabled an adequate visibility of the flap during the continuous curvilinear anterior capsulotomy (CCC). There were no i I II or postoperative complications. The endothelial cell loss varied between 1.8 percent and 26.6 percent (mean 12.8 percent). Conclusion: Staining the anterior capsule with 0.025 percent trypan blue solution allows a good visibility of the capsular flap and facilitates the confection of CCC in cataracts without red reflex.


Subject(s)
Humans , Middle Aged , Lens Capsule, Crystalline/surgery , Cataract Extraction/methods , Trypan Blue/therapeutic use , Eye Protective Devices , Phacoemulsification/methods , Lenses, Intraocular
15.
J S Afr Vet Assoc ; 67(2): 77-82, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8765067

ABSTRACT

It has been suggested that the antibabesial drug diminazene causes a rapid decline in haematocrit after treatment of dogs with high Babesia canis parasitaemias, compared with trypan blue. To test this, 19 dogs with clinically mild to moderate, uncomplicated babesiosis were placed in low, moderate or high parasitaemia groups, based on venous parasitaemias, and were allotted randomly to diminazene or trypan blue treatment groups. Haematocrit and parasitaemia were determined before treatment, and at 2, 6, 12, 18 and 24 hours. The drugs were compared for effects on haematocrit and parasite clearance. Changes in haematocrit after treatment were analysed. There were no significant differences between diminazene and trypan blue for haematocrit or parasite clearance. There was no correlation between initial parasitaemia and initial or post-treatment haematocrit. In all dogs, haematocrit fell following treatment. The maximum mean reduction from the baseline (0 h) was 0.046 l/l (range 0.02-0.07 l/l); this most often occurred at 6 or 12 h. The 24 h haematocrit ranged from 70.5-113.6% of baseline (mean absolute haematocrit 0.019 l/l below baseline). All dogs improved clinically during the study period. It was concluded that either diminazene or trypan blue can be safely used to treat dogs with clinically mild or moderate, uncomplicated babesiosis. Parasitaemia need not be taken into account when deciding which antibabesial drug to administer and does not appear to be related to the degree of anaemia.


Subject(s)
Babesiosis/drug therapy , Diminazene/therapeutic use , Dog Diseases/drug therapy , Hematocrit/veterinary , Parasitemia/drug therapy , Trypan Blue/therapeutic use , Trypanocidal Agents/therapeutic use , Analysis of Variance , Animals , Babesiosis/blood , Body Temperature , Diminazene/economics , Dog Diseases/blood , Dogs , Parasitemia/blood , Regression Analysis , Trypan Blue/economics , Trypanocidal Agents/economics
16.
Lasers Surg Med ; 12(4): 450-8, 1992.
Article in English | MEDLINE | ID: mdl-1495373

ABSTRACT

Little attention has been given to the bactericidal effect of laser irradiation, particularly using low-power energy lasers. It has been demonstrated that He-Ne laser light has an inhibitory action on dental plaque. The purpose of this study was to investigate the bactericidal effect of He-Ne laser irradiation on cariogenic microorganisms. The bactericidal effect was determined by the formation of a growth-inhibitory zone or by the counting of viable bacterial colonies. Streptococcus sobrinus AHT that is a Gram-positive microorganism was sensitive to He-Ne laser light, but Escherichia coli, a Gram-negative microorganism, was resistant. The effect of several dyes necessary to instigate a bactericidal action was also examined. A growth-inhibitory zone was observed using 10 kinds of blue, purple, or green dyes, which were mainly phenylmethane dyes. The leakage of potassium from S. sobrinus AHT following laser irradiation was determined using an atomic absorption spectrophotometer. The leakage began to increase following irradiation for 2 min, and reached a plateau following irradiation for 30-60 min. Moreover, to examine some changes in the dye itself following laser irradiation in the absence of bacteria, ultraviolet-visible absorption spectra and 1H NMR spectra were recorded. In this study, it was indicated that the bactericidal effect on cariogenic bacteria by He-Ne laser irradiation was efficient only in the presence of specific dyes. It is suggested that this laser may be suitable for clinical applications in preventive dentistry.


Subject(s)
Coloring Agents/therapeutic use , Laser Therapy , Radiation-Sensitizing Agents/therapeutic use , Streptococcus/radiation effects , Colony Count, Microbial , Dental Caries/microbiology , Deuterium , Escherichia coli/growth & development , Escherichia coli/metabolism , Escherichia coli/radiation effects , Gentian Violet/therapeutic use , Helium , Humans , Magnetic Resonance Spectroscopy , Neon , Potassium/pharmacokinetics , Spectrophotometry, Ultraviolet , Streptococcus mutans/growth & development , Streptococcus mutans/metabolism , Streptococcus mutans/radiation effects , Streptococcus sobrinus/growth & development , Streptococcus sobrinus/metabolism , Streptococcus sobrinus/radiation effects , Time Factors , Trypan Blue/therapeutic use
18.
J S Afr Vet Assoc ; 50(4): 346-52, 1979 Dec.
Article in English | MEDLINE | ID: mdl-553976

ABSTRACT

The therapeutic regime used in the treatment of dogs with Babesia canis infection differed between dogs with mild (uncomplicated) and severe (complicated) disease. In addition to the treatment given to dogs with mild disease, the dogs with severe disease received intravenous fluids, heparin and blood transfusion together with other supportive measures. Mortalities occurred only in the group with severe disease and were attributed to disseminated intravascular coagulation.


Subject(s)
Amidines/therapeutic use , Antiprotozoal Agents/therapeutic use , Babesiosis/therapy , Benzamidines/therapeutic use , Diminazene/therapeutic use , Dog Diseases/therapy , Phenyl Ethers/therapeutic use , Trypan Blue/therapeutic use , Acute Disease , Animals , Babesiosis/drug therapy , Diminazene/analogs & derivatives , Disseminated Intravascular Coagulation/complications , Dogs , Drug Therapy, Combination , Infusions, Parenteral
19.
Invest Urol ; 15(6): 496-7, 1978 May.
Article in English | MEDLINE | ID: mdl-649301

ABSTRACT

A single intraperitoneal injection of sodium oxalate was used to induce intrarenal tubular precipitation of calcium oxalate in rats. This experimental model was used to screen the efficacy of hydrochlorothiazide, orthophosphate, methylene blue, trypan blue, retinal folic acid, neuraminidase, and lysozyme in retarding intratubular calcium oxalate precipitation. Orthophosphate caused a 53 per cent reduction in calcium oxalate precipitation relative to the control animals.


Subject(s)
Urinary Calculi/drug therapy , Animals , Calcium , Disease Models, Animal , Drug Evaluation, Preclinical , Female , Folic Acid/therapeutic use , Hydrochlorothiazide/therapeutic use , Methylene Blue/therapeutic use , Muramidase/therapeutic use , Neuraminidase/therapeutic use , Oxalates , Phosphates , Rats , Trypan Blue/therapeutic use , Vitamin A/therapeutic use
20.
Int J Cancer ; 17(1): 82-9, 1976 Jan 15.
Article in English | MEDLINE | ID: mdl-1248902

ABSTRACT

Systemic administration of the synthetic immunopotentiator pyran, was as effective as the use of the biologic immunopotentiator BCG in activating macrophages and in inhibiting the Lewis lung carcinoma and MCA 2182 sarcoma. Several other synthetic polyanions also activated macrophages and exhibited some anti-tumor activity, but none were as effective as pyran. Cell-wall fractions such as the Ribi vaccine and MER were considerably less effective than BCG. The anti-tumor activity of pyran against the virtually non-immunogenic Lewis lung carcinoma involved non-specifically activated macrophages, and both anti-tumor activity and macrophage activating ability persisted over a 100-fold range of drug from 0.5 mg/kg to 50 mg/kg. The ability of activated macrophages to destroy tumor cells was abrogated by treatment with trypan blue, an inhibitor of macrophage lysosomal enzymes. In addition, preincubation of tumor cells with activated peritoneal cells at effector-cell:target-cell ratios of 20:1 and 5:1 markedly decreased tumor incidence and mortality. Glycogen-stimulated or unstimulated peritoneal cells were completely inactive in inhibiting tumor growth in vivo or exhibiting cytotoxicity in vitro, demonstrating the requirement for activated macrophages selective for tumor-cell destruction.


Subject(s)
BCG Vaccine/pharmacology , Cell Transformation, Neoplastic/drug effects , Lung Neoplasms/drug therapy , Macrophages/immunology , Pyrans/pharmacology , Sarcoma, Experimental/drug therapy , Animals , BCG Vaccine/therapeutic use , Cell Line , Lung Neoplasms/immunology , Male , Mice , Mice, Inbred C57BL , Neoplasm Transplantation , Neoplasms, Experimental/drug therapy , Pyrans/therapeutic use , Sarcoma, Experimental/immunology , Trypan Blue/pharmacology , Trypan Blue/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...